A multi-center, randomized, proof-of-concept, parallel control study with Remind Cap in patients with essential hypertension and newly treated with valsartan+/-hydrochlorothiazide (HCTZ)

Trial Profile

A multi-center, randomized, proof-of-concept, parallel control study with Remind Cap in patients with essential hypertension and newly treated with valsartan+/-hydrochlorothiazide (HCTZ)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2007

At a glance

  • Drugs Hydrochlorothiazide; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 12 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top